SCHEMBL2487009

SCHEMBL2487009

Cc1cc(Nc2nc(NC(C)c3ncc(F)cn3)c(C#N)cc2F)n[nH]1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 16/20 0.77
NTRK1 P04629 6/20 0.77
CDK2 P24941 5/20 0.77
RET P07949 2/20 0.77
FLT3 P36888 2/20 0.77
PTK2B Q14289 2/20 0.77
MUSK O15146 1/20 0.77
LCK P06239 1/20 0.77
FGFR3 P22607 1/20 0.77
CCNE1 P24864 1/20 0.77
JAK2 O60674 17/20 0.74
AURKB Q96GD4 5/20 0.74
STAT5B P51692 3/20 0.74
LIMK1 P53667 1/20 0.73
LIMK2 P53671 1/20 0.73
AURKA O14965 2/20 0.60
PLK4 O00444 1/20 0.60
STK10 O94804 1/20 0.60
PAK4 O96013 1/20 0.60
FGFR1 P11362 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2578876 0.90 JAK3 (0.78) JAK3NTRK1CDK2RETFLT3
SCHEMBL14840663 0.87 JAK3 (1.00) JAK3NTRK1CDK2RETFLT3
SCHEMBL14840664 0.87 JAK3 (1.00) JAK3NTRK1CDK2RETFLT3
SCHEMBL31061147 0.87 JAK3 (1.00) JAK3NTRK1CDK2RETFLT3
SCHEMBL2513814 0.86 JAK3 (0.59) JAK3NTRK1CDK2RETFLT3
SCHEMBL14041526 0.85 JAK2 (1.00) JAK3NTRK1CDK2RETFLT3
SCHEMBL29349780 0.84 JAK2 (1.00) JAK3NTRK1CDK2RETFLT3
SCHEMBL14840365 0.84 JAK2 (1.00) JAK3NTRK1CDK2RETFLT3
SCHEMBL14840366 0.84 JAK2 (1.00) JAK3NTRK1CDK2RETFLT3
SCHEMBL18165211 0.82 JAK2 (0.85) JAK3NTRK1CDK2RETFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2383268-B1 PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS ASTRAZENECA AB (SE) 2015-09-02 EP disclosed
US-8835465-B2 Pyrazolylaminopyridine derivatives useful as kinase inhibitors ASTRAZENECA AB (SE) 2014-09-16 US disclosed
US-20130090358-A1 PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS ASTRAZENECA AB (SE) 2013-04-11 US disclosed
EP-2383268-A1 Pyrazolylaminopyridine derivatives useful as kinase inhibitors AstraZeneca AB (SE) 2011-11-02 EP disclosed
EP-1846394-B1 PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS ASTRAZENECA AB (SE) 2011-10-26 EP disclosed
EP-2164490-A1 PYRAZOLYL DERIVATIVES WITH ANALGESIC ACTIVITY AND THEREFORE USEFUL IN THE TREATMENT OR PROPHYLAXIS OF PAIN. AstraZeneca AB (SE) 2010-03-24 EP disclosed
WO-2008054292-A1 PYRAZOLYL DERIVATIVES WITH ANALGESIC ACTIVITY AND THEREFORE USEFUL IN THE TREATMENT OR PROPHYLAXIS OF PAIN. ASTRAZENECA AB (SE) 2008-05-08 WO disclosed
US-20080108669-A1 Use 541 ASTRAZENECA AB (SE) 2008-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090358-A1 PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS MAP3K19, MAP4K2, MAP3K2 JAK3 263/4885NTRK1 1107/4885CDK2 30/4885
US-20080108669-A1 Use 541 TRPV1, P2RX3, P2RX5 JAK3 2868/4885NTRK1 3837/4885CDK2 4346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.